Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma
Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojevic, Christopher Lazarski, Abeer Shibli, Stephanie A Bien, Philip Maglo, Fahmida Hoq, Reuven Schore, Martha Glenn, Boyu Hu, Patrick J Hanley, Richard Ambinder, Catherine M Bollard, Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojevic, Christopher Lazarski, Abeer Shibli, Stephanie A Bien, Philip Maglo, Fahmida Hoq, Reuven Schore, Martha Glenn, Boyu Hu, Patrick J Hanley, Richard Ambinder, Catherine M Bollard
Abstract
Hodgkin lymphoma (HL) Reed Sternberg cells express tumor-associated antigens (TAA) that are potential targets for cellular therapies. We recently demonstrated that TAA-specific T cells (TAA-Ts) targeting WT1, PRAME, and Survivin were safe and associated with prolonged time to progression in solid tumors. Hence, we evaluated whether TAA-Ts when given alone or with nivolumab were safe and could elicit antitumor effects in vivo in patients with relapsed/refractory (r/r) HL. Ten patients were infused with TAA-Ts (8 autologous and 2 allogeneic) for active HL (n = 8) or as adjuvant therapy after hematopoietic stem cell transplant (n = 2). Six patients received nivolumab priming before TAA-Ts and continued until disease progression or unacceptable toxicity. All 10 products recognized 1 or more TAAs and were polyfunctional. Patients were monitored for safety for 6 weeks after the TAA-Ts and for response until disease progression. The infusions were safe with no clear dose-limiting toxicities. Patients receiving TAA-Ts as adjuvant therapy remain in continued remission at 3+ years. Of the 8 patients with active disease, 1 patient had a complete response and 7 had stable disease at 3 months, 3 of whom remain with stable disease at 1 year. Antigen spreading and long-term persistence of TAA-Ts in vivo were observed in responding patients. Nivolumab priming impacted TAA-T recognition and persistence. In conclusion, treatment of patients with r/r HL with TAA-Ts alone or in combination with nivolumab was safe and produced promising results. This trial was registered at www.clinicaltrials.gov as #NCT022039303 and #NCT03843294.
Trial registration: ClinicalTrials.gov NCT03843294 NCT22039303.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Figures
References
- Bollard CM, Gottschalk S, Torrano V, et al. . Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798-808.
- Bollard CM, Tripic T, Cruz CR, et al. . Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. J Clin Oncol. 2018;36(11):1128-1139.
- McLaughlin LP, Rouce R, Gottschalk S, et al. . EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018;132(22):2351-2361.
- Kochenderfer JN, Somerville RPT, Lu T, et al. . Long-duration complete remissions of diffuse large B cell lymphoma after Anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25(10):2245-2253.
- Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2018;16(10):664-666.
- Ramos CA, Ballard B, Zhang H, et al. . Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462-3471.
- Ramos CA, Grover NS, Beaven AW, et al. . Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794-3804.
- Wang CM, Wu ZQ, Wang Y, et al. . Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156-1166.
- Grover NS, Savoldo B. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019;19(1):203.
- Ansell SM, Lesokhin AM, Borrello I, et al. . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311-319.
- Armand P, Engert A, Younes A, et al. . Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial [correction published in J Clin Oncol. 2018;36(26):2748]. J Clin Oncol. 2018;36(14):1428-1439.
- Armand P, Janssens AM, Gritti G, et al. . Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021;137(5):637-645.
- Chen R, Zinzani PL, Lee HJ, et al. . Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144-1153.
- Younes A, Santoro A, Shipp M, et al. . Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283-1294.
- Hont AB, Cruz CR, Ulrey R, et al. . Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study. J Clin Oncol. 2019;37(26):2349-2359.
- Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Linchuang Zhongliuxue Zazhi. 2015;4(1):5.
- Gerdemann U, Katari U, Christin AS, et al. . Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011;19(12):2258-2268.
- Tanna JG, Ulrey R, Williams KM, Hanley PJ. Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells. Cytotherapy. 2019;21(3):278-288.
- Weber G, Caruana I, Rouce RH, et al. . Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia: implications for immunotherapy. Clin Cancer Res. 2013;19(18):5079-5091.
- Hanley PJ, Melenhorst JJ, Nikiforow S, et al. . CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015;7(285):285ra63.
- Robins HS, Campregher PV, Srivastava SK, et al. . Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114(19):4099-4107.
- Carlson CS, Emerson RO, Sherwood AM, et al. . Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4(1):2680.
- Robins H, Desmarais C, Matthis J, et al. . Ultra-sensitive detection of rare T cell clones. J Immunol Methods. 2012;375(1-2):14-19.
- Vasileiou S, Lulla PD, Tzannou I, et al. . T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects [correction published in J Clin Oncol. 2021;39(18):2053]. J Clin Oncol. 2021;39(13):1415-1425.
- Lulla P, Naik S, Vasileiou S, et al. . Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant. Blood. 2021;137(19):2585-2597.
- Lulla PD, Tzannou I, Vasileiou S, et al. . The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020;12(554):eaaz3339.
- Kvistborg P, Philips D, Kelderman S, et al. . Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014; 6(254):254ra128.
- Robert L, Tsoi J, Wang X, et al. . CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014;20(9):2424-2432.
- Yuan J, Adamow M, Ginsberg BA, et al. . Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA. 2011;108(40):16723-16728.
- Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
- De Sanctis F, Sandri S, Ferrarini G, et al. . The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. Front Immunol. 2014;5:69.
- Jain MD, Zhao H, Wang X, et al. . Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621-2633.
- Ramchandren R, Domingo-Domènech E, Rueda A, et al. . Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol. 2019;37(23):1997-2007.
- Kanate AS, Kumar A, Dreger P, et al. . Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5(5):715-722.
- Moskowitz CH, Walewski J, Nademanee A, et al. . Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-2642.
- Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812-1826.
- Koyama S, Akbay EA, Li YY, et al. . Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501.
- Lichtenegger FS, Rothe M, Schnorfeil FM, et al. . Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol. 2018;9:385.
- Foster AE, Dotti G, Lu A, et al. . Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008;31(5):500-505.
Source: PubMed